PMID- 33240086
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201127
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 11
DP  - 2020
TI  - Risperidone-Induced Obesity in Children and Adolescents With Autism Spectrum 
      Disorder: Genetic and Clinical Risk Factors.
PG  - 565074
LID - 10.3389/fphar.2020.565074 [doi]
LID - 565074
AB  - Aims: Obesity is a significant problem for patients taking atypical 
      antipsychotics. There were two aims of our study. The first aim was to compare 
      the prevalence of overweight and obesity between children and adolescents with 
      autism spectrum disorder (ASD) treated with risperidone with the general 
      pediatric population. The second aim was to investigate the association of the 
      HTR2C -759C>T, ABCB1 1236C>T, ABCB1 2677G>T/A, and ABCB1 3435C>T polymorphisms 
      with risperidone-induced overweight and obesity in children and adolescents with 
      ASD. Methods: Body weight and height were measured in 134 subjects. Overweight 
      and obesity in children and adolescents were classified using the International 
      Obesity Task Force (IOTF) criteria. Genotyping was performed by TaqMan real-time 
      polymerase chain reaction (PCR). Results: Our study found that the prevalence of 
      overweight and obesity was significantly higher in children and adolescents with 
      ASD treated with risperidone compared with healthy individuals (p = 0.01 and p = 
      0.002). The genetic polymorphisms of HTR2C -759C>T, ABCB1 1236C>T, ABCB1 
      2677G>T/A, and ABCB1 3435C>T were not associated with overweight/obesity in 
      children and adolescents with ASD treated with risperidone after adjustment for 
      multiple comparisons by the method of Bonferroni. Additionally, haplotype 
      analysis revealed that there was no significant association between ABCB1 
      3435T-2677T/A-1236T haplotype and overweight/obesity. In multivariate logistic 
      regression, after adjustment by the Bonferroni correction, there was only the 
      duration of risperidone treatment that was significantly associated with 
      overweight/obesity in children and adolescents with ASD. Conclusions: The 
      findings suggest that children and adolescents with ASD treated with risperidone 
      are at a higher risk of obesity, especially patients with extended treatment with 
      risperidone. For the pharmacogenetic factors, -759C>T polymorphism of HTR2C gene 
      and 1236C>T, 2677G>T/A, and 3435C>T polymorphisms of ABCB1 gene were not likely 
      to be associated with the susceptibility to overweight/obesity in children and 
      adolescents treated with risperidone. Due to the small sample size, further 
      studies with a larger independent group are needed to confirm these findings.
CI  - Copyright (c) 2020 Vanwong, Ngamsamut, Nuntamool, Hongkaew, Puangpetch, Limsila and 
      Sukasem.
FAU - Vanwong, Natchaya
AU  - Vanwong N
AD  - Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, 
      Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
AD  - Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), 
      Ramathibodi Hospital, Bangkok, Thailand.
AD  - Department of Clinical Chemistry, Faculty of Allied Health Sciences, 
      Chulalongkorn University, Bangkok, Thailand.
FAU - Ngamsamut, Nattawat
AU  - Ngamsamut N
AD  - Yuwaprasart Waithayopathum Child and Adolescent Psychiatric Hospital, Department 
      of Mental Health Services, Ministry of Public Health, Samut Prakan, Thailand.
FAU - Nuntamool, Nopphadol
AU  - Nuntamool N
AD  - Department of Pharmaceutical Care, Faculty of Pharmacy, Payap University, Chiang 
      Mai, Thailand.
FAU - Hongkaew, Yaowaluck
AU  - Hongkaew Y
AD  - Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, 
      Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
AD  - Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), 
      Ramathibodi Hospital, Bangkok, Thailand.
FAU - Sukprasong, Rattanaporn
AU  - Sukprasong R
AD  - Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, 
      Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
AD  - Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), 
      Ramathibodi Hospital, Bangkok, Thailand.
FAU - Puangpetch, Apichaya
AU  - Puangpetch A
AD  - Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, 
      Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
AD  - Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), 
      Ramathibodi Hospital, Bangkok, Thailand.
FAU - Limsila, Penkhae
AU  - Limsila P
AD  - Yuwaprasart Waithayopathum Child and Adolescent Psychiatric Hospital, Department 
      of Mental Health Services, Ministry of Public Health, Samut Prakan, Thailand.
FAU - Sukasem, Chonlaphat
AU  - Sukasem C
AD  - Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, 
      Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
AD  - Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), 
      Ramathibodi Hospital, Bangkok, Thailand.
LA  - eng
PT  - Journal Article
DEP - 20201106
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC7677569
OTO - NOTNLM
OT  - ABCB1
OT  - HTR2C
OT  - autism spectrum disorder
OT  - children and adolescents
OT  - obesity
OT  - risperidone
EDAT- 2020/11/27 06:00
MHDA- 2020/11/27 06:01
PMCR- 2020/11/06
CRDT- 2020/11/26 05:44
PHST- 2020/05/23 00:00 [received]
PHST- 2020/09/23 00:00 [accepted]
PHST- 2020/11/26 05:44 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2020/11/27 06:01 [medline]
PHST- 2020/11/06 00:00 [pmc-release]
AID - 565074 [pii]
AID - 10.3389/fphar.2020.565074 [doi]
PST - epublish
SO  - Front Pharmacol. 2020 Nov 6;11:565074. doi: 10.3389/fphar.2020.565074. 
      eCollection 2020.